Background: Alirocumab is a monoclonal antibody that inhibits binding of PCSK9 to LDL
receptors, decreasing their lysosomal degradation and increasing their numbers on cell …

Background: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin
type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein …

Background: Proprotein convertase subtilisin/kexin type (PCSK9) inhibitors are promising
new drugs for the treatment of hypercholesterolemia. They inhibit the binding of PCSK9 to …

Background Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin
type 9 (PCSK9). Objective Changes in PCSK9, alirocumab, and low-density lipoprotein …

Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9
antibodies on triglyceride metabolism are less pronounced. The present study aimed to …

Background Alirocumab undergoes target‐mediated clearance via binding of proprotein
convertase subtilisin/kexin type 9 (PCSK 9). Statins increase PCSK 9 levels; the effects of …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy
for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 …

The proof of concept that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
affects cholesterol levels was first established after the demonstration that PCSK9 loss-of …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in lipoprotein
metabolism, mainly by modulating LDL receptor activity. Alirocumab is a fully human IgG1 …

Background The ODYSSEY CHOICE I study (NCT01926782) evaluated alirocumab 300 mg
every 4 weeks (Q4W) in patients with hypercholesterolemia receiving maximally tolerated …